MANKIND PHARMA SHARE PRICE

Shares of Wockhardt surged 18% in early trading to reach a new 52-week high of Rs 811.50 on NSE. The sharp increase followed the company's announcement of the successful use of its investigational antibiotic, Zaynich (Zidebactam/CefepimeWCK 5222), i...

Post their numbers and the management guidance of single-digit growth in the current year, we have seen a decent fall in Sun Pharma. Overall the stock continues to remain strong in the specialty and the overall businesses. The risk versus reward and...

Despite the Nifty index closing the shortened trading week with a slight increase of 0.4%, significant activity was observed in block deals. Over three dozen companies across various market caps saw block deals worth a total of ₹40,543 crore, involv...

Shares of Delta Corp, the sole listed company in India's casino gaming industry, saw a significant surge of nearly 15%. This increase in stock price came amidst expectations that the Goods and Services Tax (GST) Council might review the tax structur...

Shares of Gland pharma fell 3.7% as Shanghai-based Fosun Pharma offloaded a 6.2% stake in a block deal managed by UBS, decreasing its holding from 75% to 58.36%.

Fosun will sell the shares at Rs 1750 per share which is 4.9% discount to the last traded price of Rs 1839.65. Fosun currently has a 57.86 percent shareholding in Gland Pharma.

Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and target price of Rs 2,650. The company's disruptive strategy in establishing its DF business has made it an industry leader in prescriptions.

Top brokerage firms like Motilal Oswal, Jefferies, and Morgan Stanley have issued buy ratings and targets for Mankind Pharma, Nykaa, Tata Consumer, and Varun Beverages.

​But our overall sense is that one needs to sort of watch out for Budget plus the element of optimism. Although they have some head room in terms of higher RBI dividend plus, obviously there can be structural savings on the subsidy side especially r...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 89132.93 Crore) operating in Pharmaceuticals sector.

The pharma stock is a part of the S&P BSE Smallcap index. It saw an uptrend, rising from Rs 393 as of June 9, 2023, to Rs 901 recorded on June 10, 2024. It has, however, undergone mild consolidation of approximately 100 points since April on the dai...

The week was an eventful one. Besides the general election results, D-Street saw some prominent block deals which included over three dozen companies from large, mid and smallcap segments. Shares worth Rs 7,640 crore were traded on screen, which inc...

Defensive sectors like FMCG and pharma are emerging as potential winners under Modi 3.0, with experts forecasting gains fueled by rural push and policy actions. Investors are advised to explore stocks like HUL, Dabur, and pharma majors for potential...

In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sen...

Sanjiv Bhasin says Mankind has been a revelation purely on the back of some of the launches which have been well accepted and their domestic business has actually been way ahead of most of the peers. There is margin on the upside given that it is en...

Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.

Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its board approved the raising of funds worth Rs 7,500 crore via the issuance of equity shares. For the full financ...

Benchmark equities surged for the third consecutive day on Tuesday. PFC, Mankind Pharma, Patanjali Foods, Bharti Airtel, Siemens, and Cipla are in focus for news developments and quarterly results. RVNL, Dixon, and Titagarh will also announce their ...

PE firm ChrysCapital's affiliate entity Beige Ltd was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares of Mankind Pharma at a price range of Rs 2,103.21 to Rs 2,214 per share.